» Articles » PMID: 36553623

Clonal Elimination of the Pathogenic Allele As Diagnostic Pitfall in -Associated Neuropathy

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2022 Dec 23
PMID 36553623
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Heterozygous gain-of-function variants in are associated with ataxia-pancytopenia syndrome (ATXPC) and monosomy 7 myelodysplasia and leukemia syndrome-1 (M7MLS1). Association with peripheral neuropathy has rarely been described.

Methods: Whole-exome sequencing (WES) from DNA extracted from peripheral blood was performed in a 10-year-old female presenting with demyelinating neuropathy, her similarly affected mother and the unaffected maternal grandparents. In addition to evaluation of single nucleotide variants, thorough work-up of copy number and exome-wide variant allele frequency data was performed.

Results: Combined analysis of the mother's and daughter's duo-exome data and analysis of the mother's and her parents' trio-exome data initially failed to detect a disease-associated variant. More detailed analysis revealed a copy number neutral loss of heterozygosity of 7q in the mother and led to reanalysis of the exome data for respective sequence variants. Here, a previously reported likely pathogenic variant in the gene on chromosome 7q (NM_152703.5:c.2956C>T; p.(Arg986Cys)) was identified that was not detected with standard filter settings because of a low percentage in blood cells (13%). The variant also showed up in the daughter at 32%, a proportion well below the expected 50%, which in each case can be explained by clonal selection processes in the blood due to this variant.

Conclusion: The report highlights the specific pitfalls of molecular genetic analysis of and, furthermore, shows that gain-of-function variants in this gene can lead to a clinical picture associated with the leading symptom of peripheral neuropathy. Due to clonal hematopoietic selection, displacement of the mutant allele occurred, making diagnosis difficult.

Citing Articles

Genetic and clinical spectrum of SAMD9 and SAMD9L syndromes: from variant interpretation to patient management.

Sahoo S, Erlacher M, Wlodarski M Blood. 2024; 145(5):475-485.

PMID: 39475954 PMC: 11826520. DOI: 10.1182/blood.2022017717.


The evolving spectrum of complex inherited neuropathies.

Rossor A, Haddad S, Reilly M Curr Opin Neurol. 2024; 37(5):427-444.

PMID: 39083076 PMC: 11377048. DOI: 10.1097/WCO.0000000000001307.


Quality assurance within the context of genome diagnostics (a german perspective).

Florian K, Benet-Pages A, Berner D, Teubert A, Eck S, Arnold N Med Genet. 2024; 35(2):91-104.

PMID: 38840862 PMC: 10842579. DOI: 10.1515/medgen-2023-2028.


Assessing Long-Term Neurologic Outcomes in SAMD9L-Related Ataxia-Pancytopenia Syndrome.

Zingariello C, Chen D, Raskind W, Slayton W, Subramony S, Severance J Mov Disord Clin Pract. 2024; 11(6):728-733.

PMID: 38594844 PMC: 11145150. DOI: 10.1002/mdc3.14038.

References
1.
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

2.
Guo Y, Ding X, Shen Y, Lyon G, Wang K . SeqMule: automated pipeline for analysis of human exome/genome sequencing data. Sci Rep. 2015; 5:14283. PMC: 4585643. DOI: 10.1038/srep14283. View

3.
Allenspach E, Soveg F, Finn L, So L, Gorman J, Rosen A . Germline SAMD9L truncation variants trigger global translational repression. J Exp Med. 2021; 218(5). PMC: 7970252. DOI: 10.1084/jem.20201195. View

4.
King-Robson J, Marshall J, Smith F, Willoughby L, Mansour S, Sztriha L . Ataxia-Pancytopenia Syndrome due to a de Novo Mutation. Neurol Genet. 2021; 7(3):e580. PMC: 8054956. DOI: 10.1212/NXG.0000000000000580. View

5.
Collin M . I am : 7q regulator I am. Blood. 2017; 129(16):2210-2212. DOI: 10.1182/blood-2017-03-770198. View